Neurizon Therapeutics Limited has released a press release.
Interim analysis recommended in MND trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- European Patent relating to MPL Combinations in Cancer
- First Patient of Cohort 2 Dosed in MND Trial
- PharmAust canine trial update
- PharmAust Progresses to Elevated Doses in MND Patients
- MND Trial Successfully Completes First Patient Cohort
Later from Neurizon Therapeutics
- Canine Cancer Trial Update
- Stable Patient in MND trial reaches 6-months on MPL
- MND Trial Completes Enrolment of Cohort 2
- PharmAust launches international CEO search
- Arrival of additional MPL tablets
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics